ONTARIO

FIRAZYR is covered by Ontario Exceptional Access Program

Eligibility

For FIRAZYR to be eligible for coverage under Ontario’s Exceptional Access Program, prescribers must submit a request to the Exceptional Access Program and the request must be approved before the patient fills the prescription. Deductibles may apply. For more information concerning the reimbursement process, contact OnePath®.

Reimbursement Criteria

We are pleased to inform you that FIRAZYR (icatibant acetate) is reimbursed in Ontario for your hereditary angioedema (HAE) patients who meet the following criteria:

For the treatment of acute attacks of type 1 or type II HAE in adults with lab confirmed C1-esterase inhibitor deficiency if the following conditions are met:

  • Treatment of acute non-laryngeal attacks of at least moderate severity, OR
  • Treatment of acute laryngeal attacks, AND
  • Must be prescribed by physicians (e.g., immunologists, allergists or hematologists) with experience in the treatment of HAE

Notes:

  • Documentation of diagnosis (e.g., patient and family history, symptoms, lab test results) must be provided
  • For acute non-laryngeal attacks, documentation of severity (frequency, location, and degree of swelling) must be provided

Doses for acute treatment are limited to a single dose for self-administration per attack.

Duration of Approval: Lifetime

OnePath® Patient Support Program will help navigate insurance coverage and access reimbursement to medication through private and public insurance companies.

Find Out More

Source: Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs. January 2022.
http://health.gov.on.ca/en/pro/programs/drugs/docs/frequently_requested_drugs.pdf